肾移植受者接受腹主动脉瘤腔内修复术后围手术期急性肾损伤风险增加但远期死亡率无差异
肾移植受者术后急性肾损伤发生率更高(9.4% vs 2.7%),校正后比值比3.33,但需新发肾替代治疗、术后死亡及5年生存率无差异。
要点
- 肾移植受者择期EVAR术后急性肾损伤发生率9.4%,显著高于非移植患者的2.7%。
- 校正混杂因素后,肾移植与术后急性肾损伤风险独立相关(OR 3.33,95%CI 1.93-5.76)。
- 肾移植受者5年总体生存率与非移植患者相似(83.4% vs 80%)。
核心结论
- 择期肾下EVAR的肾移植受者术后急性肾损伤风险独立升高,但需肾替代治疗的肾衰竭、死亡、内漏、主动脉相关再干预及主要不良心脏事件未见增加,5年生存率相似。
- 作者建议对肾移植受者采取积极且最大程度优化的肾脏保护措施以降低术后急性肾损伤风险。
研究设计与样本
- 回顾性队列研究,查询血管质量倡议数据库2003至2021年所有择期EVAR患者。
主要发现
- 肾移植受者较非移植患者更年轻(中位71岁 vs 74.5岁,P < .001),高血压(92% vs 84%,P = .004)和糖尿病(29% vs 21%,P = .005)发生率更高。
- 肾移植受者术前中位血肌酐更高(1.3 mg/dL vs 1.0 mg/dL,P < .001),估算肾小球滤过率更低(51.6 mL/min vs 69.4 mL/min,P < .001)。
- 肾移植受者更常采用全身麻醉,造影剂用量更少(中位68.6 mL vs 94.8 mL,P < .001),晶体液输注更多(中位1700 mL vs 1500 mL,P = .039)。
- 术后急性肾损伤发生率肾移植受者更高(9.4% vs 2.7%,P < .001),但需新发肾替代治疗的比例相似(1.1% vs 0.4%,P = .15)。
- 校正混杂因素后,肾移植与术后急性肾损伤风险升高相关(OR 3.33,95%CI 1.93-5.76,P < .001);亚组分析中糖尿病与肾移植受者术后急性肾损伤风险升高相关(OR 4.21,95%CI 1.17-15.14,P = .02)。
临床怎么用
- 作者认为,尽管EVAR在围手术期可能带来相当的获益和技术成功率,肾移植受者仍应采取积极且最大程度优化的肾脏保护措施以降低术后急性肾损伤风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Renal transplant is associated with substantial survival advantage in patients with end-stage renal disease. However, little is known about the outcomes of renal transplant recipients (RTRs) after endovascular abdominal aortic aneurysm repair (EVAR). This study aimed to study the effect of renal transplant on perioperative outcomes and long-term survival after elective infrarenal EVAR. METHODS: The Vascular Quality Initiative database was queried for all patients undergoing elective EVAR from 2003 to 2021. Functioning RTRs were compared with non-renal transplant recipients without a diagnosis of end-stage renal disease (non-RTRs). The outcomes included 30-day mortality, acute kidney injury (AKI), new renal failure requiring renal replacement therapy (RRT), endoleak, aortic-related reintervention, major adverse cardiac events, and 5-year survival. A logistic regression analysis was used to assess the association between RTRs and perioperative outcomes. RESULTS: Of 60,522 patients undergoing elective EVAR, 180 (0.3%) were RTRs. RTRs were younger (median, 71 years vs 74.5 years; P < .001), with higher incidence of hypertension (92% vs 84%; P = .004) and diabetes (29% vs 21%; P = .005). RTRs had higher median preoperative serum creatinine (1.3 mg/dL vs 1.0 mg/dL; P < .001) and lower estimated glomerular filtration rate (51.6 mL/min vs 69.4 mL/min; P < .001). There was no difference in the abdominal aortic aneurysm diameter and incidence of concurrent iliac aneurysms. Procedurally, RTRs were more likely to undergo general anesthesia with lower amount of contrast used (median, 68.6 mL vs 94.8 ml; P < .001) and higher crystalloid infusion (median, 1700 mL vs 1500 mL; P = .039), but no difference was observed in the incidence of open conversion, endoleak, operative time, and blood loss. Postoperatively, RTRs experienced a higher rate of AKI (9.4% vs 2.7%; P < .001), but the need for new RRT was similar (1.1% vs 0.4%; P = .15). There was no difference in the rates of postoperative mortality, aortic-related reintervention, and major adverse cardiac events. After adjustment for potential confounders, RTRs remained associated with increased odds of postoperative AKI (odds ratio, 3.33; 95% confidence interval, 1.93-5.76; P < .001) but had no association with other postoperative complications. A subgroup analysis identified that diabetes (odds ratio, 4.21; 95% confidence interval, 1.17-15.14; P = .02) is associated with increased odds of postoperative AKI among RTRs. At 5 years, the overall survival rates were similar (83.4% vs 80%; log-rank P = .235). CONCLUSIONS: Among patients undergoing elective infrarenal EVAR, RTRs were independently associated with increased odds of postoperative AKI, without increased postoperative renal failure requiring RRT, mortality, endoleak, aortic-related reintervention, or major adverse cardiac events. Furthermore, 5-year survival was similar. As such, while EVAR may confer comparable benefits and technical success perioperatively, RTRs should have aggressive and maximally optimized renal protection to mitigate the risk of postoperative AKI.
引用
- Chang H, Veith FJ, Laskowski I, et al. Renal transplant recipients undergoing endovascular abdominal aortic aneurysm repair have increased risk of perioperative acute kidney injury but no difference in late mortality. J Vasc Surg. 2023. PMID: 36626957. doi:10.1016/j.jvs.2022.12.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。